Brief: Invex Therapeutics Files Pre-Ind/Type B Meeting Request With US FDA
31/03/2021 02:24
March 31 (Reuters) - Invex Therapeutics Ltd IXC.AX :
* FILES PRE-IND/TYPE B MEETING REQUEST WITH US FDA
* MEETING REQUEST FOR SEEKING FURTHER PROTOCOL ASSISTANCE ON
A
PROPOSED PHASE III CLINICAL TRIAL OF PRESENDIN (EXENATIDE)
Source text for Eikon: ID:nASX7r6HGG
Further company coverage: IXC.AX
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Invex Therapeutics
See all newsBrief: Invex Therapeutics Requests Trading Halt
Brief: Invex Therapeutics Says Narelle Warren Resigns As CFO
Brief: Invex Therapeutics' Negotiations Discontinued With Neurological Disease Therapeutics Development Co
Australia's Invex Therapeutics falls as agreement talks fade
Brief: Invex Therapeutics Seeks Trading Halt